Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 53

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 53
---
10-K from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 21, 2025.

•

Our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on May 5, 2025and August 13, 2025, respectively.

•

Our Current Reports on Form 8-K filed with the SEC on January 7, 2025, January 13, 2025, June 16, 2025and June 17, 2025.

•

The description of our common stock contained in the “Description of the Securities” filed as Exhibit 4.3to our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 10, 2022, and any amendment or report filed with the SEC for the purpose of updating the description.

All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the “Exchange Act” in this prospectus, prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents.

<div align='center'>3</div>

TABLE OF CONTENTS

You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or telephoning us at the following address:

#### Immuneering Corporation

#### 245 Main Street, Second Floor

#### Cambridge, MA 02142
<div align='center'>**(617) 500-8080**</div>

Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any accompanying prospectus supplement.

<div align='center'>4</div>

TABLE OF CONTENTS

### THE COMPANY
We are a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. We aim to achieve this goal through Deep Cyclic Inhibition, or DCI